key: cord-0788967-4248sv84
authors: Kakuturu, Jahnavi; McCluskey, Casey; Casey, Francis L.; Cicek, Sertac; Hayanga, J. W. Awori
title: Extracorporeal Membrane Oxygenation to treat a 15-year-old Patient with Severe COVID-19 Respiratory Failure
date: 2021-03-18
journal: JTCVS Tech
DOI: 10.1016/j.xjtc.2021.03.012
sha: 938ba22a25cd609f4f1e8d55e8f5ac8d75e1388c
doc_id: 788967
cord_uid: 4248sv84

nan

Informed consent was obtained from the patient's mother for publication of this case report. Severe acute respiratory distress syndrome (ARDS) secondary to a novel coronavirus, COVID-25 19 (SARS-CoV-2) was first reported in Wuhan, China in December 2019, and quickly spread to 26 become a global pandemic. Children are less commonly affected but those with complex medical 27 histories may be susceptible to severe forms of disease with a mortality rate of almost 5% 1 . We 28 present the case of a pediatric patient with multiple comorbidities who presented with SARS-29

CoV-2 and was successfully treated with veno-venous extracorporeal membrane oxygenation 30 (VV-ECMO). 31

A 15-year-old female with a history of morbid obesity (body mass index of 56), hypertension, 34 hypothyroidism, pre-diabetes, and asthma, presented to an affiliated institution with cough, 35 shortness of breath, and fatigue. On presentation to the emergency department, her oxygen 36 saturation (SpO2) was 55% on room air and increased to 88% on 15L/min non-rebreather. Due 37 to her severe hypoxic respiratory failure, she was admitted to the pediatric intensive care unit 38 (PICU), intubated and placed on mechanical ventilation. Her requirements escalated 39 necessitating transfer to our institution for higher level of care. On arrival, she had a PaO2:FiO2 40 ratio of 55, consistent with a diagnosis of severe ARDS. Her confirmatory nasopharyngeal 41 polymerase chain reaction test was positive for COVID-19, and chest radiograph revealed 42 pathognomonic bilateral pulmonary parenchymal opacities (figure 1). She was initiated on 43 intravenous antibiotics, Dexamethasone, enoxaparin anticoagulation, inhaled nitric oxide (40 44 ppm), and proned. Convalescent plasma therapy and intravenous Remdesivir (Gilead Sciences 45 Inc) were also administered. She developed acute oliguric renal injury and diastolic hypotension 46 requiring low dose Norepinephrine infusion. Remdesivir was discontinued given the 47 deterioration in renal function. The ECMO team was consulted for persistent PF ratio < 80 for 48 several hours. Following multidisciplinary evaluation, she was deemed a candidate for VV-49 ECMO as a bridge to recovery. 

Day 5 to mitigate the cytokine storm. Bronchioalveolar lavage and blood cultures obtained were 58 negative. On ECMO-Day 9 she underwent a second session of TPE which normalized her 59 inflammatory markers. On ECMO-Day 10, she was weaned off gases and successfully 60 decannulated requiring oxygen at 4L/min nasal cannula with SpO2 > 95%. She transferred out 61 of the PICU two days post ECMO decannulation. Thereafter, she continued to recover and was 62 discharged home 7 days later after a total hospitalization of 19 days. Informed consent was 63 obtained from the patient's mother for publication of case data. 

Characteristics and Outcomes of 117

COVID-19) Infection Admitted to US and 118

Canadian Pediatric Intensive Care Units

Clinical characteristics of COVID-19 in 120 children: A systematic review

COVID-19 in children and 122 adolescents in Europe: a multinational, multicentre cohort study

Extracorporeal membrane oxygenation in 125 children with COVID-19: Preliminary report from the collaborative EuroELSO 126 prospective survey

Therapeutic Plasma Exchange: 128 A potential Management Strategy for Critically Ill COVID-19 Patients